Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study

Authors

Institutions

Publication Details

Journal
Expert Opinion on Investigational Drugs
Published
2026-02-01
DOI
https://doi.org/10.1080/13543784.2026.2628208
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study

Kim Papp, Michio Yagi, JungBin Cha, Eunkyung Euni Lee et al.
Expert Opinion on Investigational Drugs
Biosimilars and Bioanalytical Methods
article

Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study

Kim Papp, Michio Yagi, JungBin Cha, Eunkyung Euni Lee, Diamant Thaçi, Tomoko Hasunuma, JeeHye Suh, IIn Noh, Noboru Nakamichi, Andrew Blauvelt
article en

Abstract

No abstract available for this paper.
Expert Opinion on Investigational DrugsVol. 35(2)
University of Toronto (CA), Alliance for Clinical Trials in Oncology (US), Probity Medical Research (CA), Kitasato Institute Hospital (JP), Celltrion (South Korea) (KR), Kitasato University (JP), University of Lübeck (DE)
Openalex Percentile: Top 60%
Biosimilars and Bioanalytical Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.